Literature DB >> 25727719

Importance of contralateral aldosterone suppression during adrenal vein sampling in the subtype evaluation of primary aldosteronism.

Hironobu Umakoshi1, Kanako Tanase-Nakao1, Norio Wada2, Takamasa Ichijo3, Masakatsu Sone4, Nobuya Inagaki4, Takuyuki Katabami5, Kohei Kamemura6, Yuichi Matsuda7, Yuichi Fujii8, Tatsuya Kai9, Tomikazu Fukuoka10, Ryuichi Sakamoto11, Atsushi Ogo11, Tomoko Suzuki12, Mika Tsuiki1, Akira Shimatsu1, Mitsuhide Naruse1.   

Abstract

OBJECTIVES: Adrenal vein sampling (AVS) is the standard criterion for the subtype diagnosis in primary aldosteronism (PA). Although lateralized index (LI) ≥4 after cosyntropin stimulation is the commonly recommended cut-off for unilateral aldosterone hypersecretion, many of the referral centres in the world use LI cut-off of <4 without sufficient evidence for its diagnostic accuracy. AIM: The aim of the study was to establish the diagnostic significance of contralateral (CL) aldosterone suppression for the subtype diagnosis in patients with LI <4 in AVS. DESIGN AND PATIENTS: A retrospective multicentre study was conducted in Japan. Of 124 PA patients subjected to unilateral adrenalectomy after successful AVS with cosyntropin administration, 29 patients with LI < 4 were included in the study. The patients were divided into Group A with CL suppression (n = 16) and Group B (n = 13) without CL suppression. Three outcome indices were assessed after 6 months postoperatively: normalization/significant improvement of hypertension, normalization of the aldosterone to renin ratio (ARR) and normalization of hypokalaemia.
RESULTS: The normalization/significant improvement of hypertension was 81% in Group A and 54% in Group B (P = 0·2). The normalization of ARR was 100% in Group A and 46% in Group B (P = 0·004). Hypokalaemia was normalized in all patients of both groups. The overall cure rate of PA based on meeting all the three criteria was 81% in Group A and 31% in Group B (P = 0·01).
CONCLUSIONS: In patients with PA, where the LI is <4 on AVS, CL suppression of aldosterone is an accurate predictor of a unilateral source of aldosterone excess. CL suppression data should be interpreted in conjunction with computed tomographic adrenal imaging findings to guide surgical management.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25727719     DOI: 10.1111/cen.12761

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Historical changes and between-facility differences in adrenal venous sampling for primary aldosteronism in Japan.

Authors:  Yuichi Fujii; Yoshiyu Takeda; Isao Kurihara; Hiroshi Itoh; Takuyuki Katabami; Takamasa Ichijo; Norio Wada; Yui Shibayama; Takanobu Yoshimoto; Yoshihiro Ogawa; Junji Kawashima; Masakatsu Sone; Nobuya Inagaki; Katsutoshi Takahashi; Minemori Watanabe; Yuichi Matsuda; Hiroki Kobayashi; Hirotaka Shibata; Kohei Kamemura; Michio Otsuki; Koichi Yamamto; Atsushi Ogo; Toshihiko Yanase; Shintaro Okamura; Shozo Miyauchi; Megumi Fujita; Tomoko Suzuki; Hironobu Umakoshi; Tatsuki Ogasawara; Mika Tsuiki; Mitsuhide Naruse
Journal:  J Hum Hypertens       Date:  2019-08-28       Impact factor: 3.012

2.  Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism.

Authors:  Aya T Nanba; Kazutaka Nanba; James B Byrd; James J Shields; Thomas J Giordano; Barbara S Miller; William E Rainey; Richard J Auchus; Adina F Turcu
Journal:  Clin Endocrinol (Oxf)       Date:  2017-09-04       Impact factor: 3.478

3.  Improved adrenal vein sampling from a dedicated programme: experience of a low-volume single centre in Singapore.

Authors:  Min-On Tan; Troy Hai Kiat Puar; Saravana Kumar Swaminathan; Yu-Kwang Donovan Tay; Tar Choon Aw; David Yurui Lim; Haiyuan Shi; Lily Mae Quevedo Dacay; Meifen Zhang; Joan Joo Ching Khoo; Keng Sin Ng
Journal:  Singapore Med J       Date:  2020-12-02       Impact factor: 3.331

4.  Adrenal Vein Sampling for Conn's Syndrome: Diagnosis and Clinical Outcomes.

Authors:  Amy R Deipolyi; Alexander Bailin; Stephan Wicky; Shehab Alansari; Rahmi Oklu
Journal:  Diagnostics (Basel)       Date:  2015-06-19

Review 5.  New Advances in the Diagnostic Workup of Primary Aldosteronism.

Authors:  Martin J Wolley; Michael Stowasser
Journal:  J Endocr Soc       Date:  2017-01-27

Review 6.  Subtype Diagnosis of Primary Aldosteronism: Is Adrenal Vein Sampling Always Necessary?

Authors:  Fabrizio Buffolo; Silvia Monticone; Tracy A Williams; Denis Rossato; Jacopo Burrello; Martina Tetti; Franco Veglio; Paolo Mulatero
Journal:  Int J Mol Sci       Date:  2017-04-17       Impact factor: 5.923

7.  Clinical outcomes of primary aldosteronism based on lateralization index and contralateral suppression index after adrenal venous sampling in real-world practice: a retrospective cohort study.

Authors:  Jeongmin Lee; Borami Kang; Jeonghoon Ha; Min-Hee Kim; Byungil Choi; Tae-Ho Hong; Moo Il Kang; Dong-Jun Lim
Journal:  BMC Endocr Disord       Date:  2020-07-29       Impact factor: 2.763

8.  Factors Associated with Resolution of Hypertension after Adrenalectomy in Patients with Primary Aldosteronism.

Authors:  Wann Jia Loh; Dawn Shao Ting Lim; Lih Ming Loh; Peng Chin Kek
Journal:  Endocrinol Metab (Seoul)       Date:  2018-08-14

9.  Primary aldosteronism subtyping in the setting of partially successful adrenal vein sampling.

Authors:  Seung-Eun Lee; Sung Woon Park; Min Sun Choi; Gyuri Kim; Jee Hee Yoo; Jiyeon Ahn; Ji Eun Jun; Hong Suk Park; Dongho Hyun; Sung Ki Cho; Seong Eun Ko; Beom-Jun Kim; Jong Woo Kim; Hyun-Ki Yoon; Jung-Min Koh; Seung Hun Lee; Jae Hyeon Kim
Journal:  Ther Adv Endocrinol Metab       Date:  2021-02-13       Impact factor: 3.565

10.  Contralateral Suppression at Adrenal Venous Sampling Is Associated with Renal Impairment Following Adrenalectomy for Unilateral Primary Aldosteronism.

Authors:  Ye Seul Yang; Seung Hun Lee; Jung Hee Kim; Jee Hee Yoo; Jung Hyun Lee; Seo Young Lee; A Ram Hong; Dong-Hwa Lee; Jung-Min Koh; Jae Hyeon Kim; Sang Wan Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.